Fig. 5

(a) PDI images of HepG2 tumors at different time points, pre-, post- and 7 day post-treatment with SOR@LDH-CuS/P. (b) Fluorescence images of mice after injection of FITC-labeled dextran. (c) Fluorescence images of mice after injection of SOR@LDH-CuS/P and SOR@LDH-CuS modified with Cy7 at various time points. (d) Tumor growth tendency, (e) corresponding average tumor weight and (f) digital photographs of mice with different treatments: (1) PBS + NIR, (2) LDH-CuS/P, (3) LDH-CuS/P + NIR, (4) SOR, (5) SOR@LDH-CuS/P, (6) SOR@LDH-CuS/P + NIR. Data are presented as mean values ± s.d. (n = 6). ***p < 0.001. (g) H&E, TUNEL, CD31 and CD34 staining assays of tumor tissue slices from different groups of mice after 16-day treatment